Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (18613)	6/8/2006 10:00:51 PM
From: tnsaf	Respond to of 52153

NeoPharm Announces PRECISE Trial Has Reached Criteria for Interim Efficacy Analysis; Independent Data Monitoring Committee to Conduct Interim Efficacy Analysis 6/8/2006 8:40:00 AM EST BIOWIRE NeoPharm (Nasdaq:NEOL) today announced that it has received notification that the Company's cintredekin besudotox (IL13-PE38QQR) Pivotal Phase III PRECISE trial for the treatment of Glioblastoma Multiforme (GBM), the most aggressive form of brain cancer, has reached the criterion for the interim efficacy statistical analysis (160 deaths). As a result, the PRECISE trial's independent Data Monitoring Committee (DMC) will assess the study data to date, conduct an interim efficacy analysis, and thereafter provide its recommendation to the Company. The Company currently expects to receive the DMC's recommendation within 10-14 business days. In accordance with the Study protocol, an interim efficacy analysis will be conducted by the DMC to evaluate potential superiority of long-term patient survival of cintredekin besudotox versus Gliadel(R) Wafer. The DMC will inform the company that it has reached the pre-specified statistical endpoint or continue to the final efficacy analysis at the 215th death, expected to occur in late 2006 or early 2007.